New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ (telbivudine), USFDA-Approved
TYZEKA™ (telbivudine), a product of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), has recently been approved by the USFDA as a new once-a-day oral treatment (taken with or without food) for patients with chronic hepatitis B (CHB).
TYZEKA™, which demonstrated abililty to rapidly and profoundly suppress the hepatitis B virus (HBV) in adult patients, is the first Idenix drug to obtain USFDA approval.
According to Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer at Idenix Pharmaceuticals, Inc.:
"The FDA approval of TYZEKA is a major milestone for Idenix as it is the first Idenix drug to receive U.S. approval Receiving approval just six years after TYZEKA entered clinical development is a tremendous accomplishment and demonstrates Idenix's commitment to discovering and developing new treatment options for patients affected by devastating viral diseases."Find more details of the clinical results that lead to the USFDA approval from the press release.
Comment Preview